I am a board-certified medical oncologist whose clinical practice is dedicated exclusively to the care of patients with all stages of breast cancer. I am part of a large, multidisciplinary team of devoted specialists who share my goal of providing exceptional care to patients fighting breast cancer. Through my research activities, I work to develop new therapeutic options for the treatment of breast cancer and to ultimately eradicate this disease.
My research has centered on the use of novel, targeted therapies for the treatment of triple negative breast cancer (TNBC). Currently, I am the lead investigator for a multicenter trial studying the use of androgen receptor inhibition for patients with advanced TNBC. I have investigated numerous other targets for treatment of this subtype of breast cancer, including src and PARP, and have collaborated to develop biologic predictors of response to conventional therapies such as platinum. I have also had a special interest in optimizing drug delivery schedules to minimize side effects of treatment while maximizing its benefits.
I have received grant support for my work from the Breast Cancer Alliance and the Translational Breast Cancer Research Consortium (TBCRC) — a nationwide panel of centers of excellence in breast cancer medicine — where I also serve on the Triple Negative Breast Cancer working group panel. I have lectured internationally and presented our research findings at forums including the annual San Antonio Breast Cancer Symposium and the annual meeting of the American Society of Clinical Oncology (ASCO). I am a member of the New York Metropolitan Breast Cancer Group and serve on the editorial board of the European Journal of Clinical & Medical Oncology. Additionally, I am an ad hoc reviewer for several clinical journals and have published in scientific journals including the Journal of Clinical Oncology, Clinical Cancer Research, and Mi
I am committed to providing compassionate care to my patients as they undergo treatment for their breast cancer.
- Clinical Expertise: Breast Cancer
- Languages Spoken: English
- Education: MD, Weill Cornell Medical College
- Residencies: NewYork-Presbyterian Hospital/Weill Cornell Medical Center
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Tiffany A. Traina
- A Phase I Study of Enzalutamide (MDV3100) in Patients with Previously Treated Metastatic Breast Cancer
- A Phase II Study of Dose-Dense Doxorubicin and Cyclophosphamide followed by Eribulin Mesylate for the Adjuvant Treatment of Early-Stage Breast Cancer
- A Phase II Study of Exemestane with and without Enzalutamide in Women with Advanced Hormone Receptor-Positive Breast Cancer
Clinical Trials Co-Investigated by Tiffany A. Traina
- A Phase II Study of BMN 673 (Talazoparib) in Patients with Locally Advanced or Metastatic Breast Cancer Containing a BRCA Mutation
- A Phase II Study of Neoadjuvant Letrozole with and without GDC-0032 in Postmenopausal Women with Early-Stage Estrogen-Receptor-Positive, HER2-Negative Breast Cancer
- A Phase III Study of Olaparib versus Standard Chemotherapy to Treat Patients with Metastatic Breast Cancer Who Have BRCA Mutations